Instrument Inactif

Communiqués Imprimis Pharmaceuticals Inc Nasdaq

Actions

US45323A2015

Produits pharmaceutiques

Communiqués

01/07	Harrow Announces Commercial Launch of BYOOVIZ® in the United States	AQ
10/06	Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare	AQ
27/05	Harrow to Present at William Blair’s 46th Annual Growth Stock Conference	AQ
13/05	HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations	AQ
11/05	Harrow : Q1-2026 Letter to Stockholders	PU
11/05	Harrow: Q1 Earnings Snapshot	AQ
11/05	Harrow Announces First Quarter 2026 Financial Results	AQ
27/04	Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026	AQ
21/04	Harrow Announces the Issuance of J-Code for IOPIDINE® 1%	AQ
14/04	LogiCare3PL Selected as Distribution Partner by Harrow	PR
24/03	Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030	AQ
24/03	Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth	AQ
18/03	Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting	AQ
05/03	Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference	AQ
04/03	Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication	AQ
04/03	Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference	AQ
03/03	Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication	AQ
02/03	Harrow: Q4 Earnings Snapshot	AQ
02/03	Harrow : Q4-2025 Letter to Stockholders	PU
02/03	Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance	AQ
18/02	Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026	AQ
17/02	Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits	AQ
02/02	Harrow : Initial Statement of Beneficial Ownership (Form 3)	PU
02/02	Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth	AQ
24/11	Harrow to Present at Two Investor Conferences in December	AQ